BRIMONIDINE P SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

BRIMONIDINE TARTRATE

Beschikbaar vanaf:

AA PHARMA INC

ATC-code:

S01EA05

INN (Algemene Internationale Benaming):

BRIMONIDINE

Dosering:

0.15%

farmaceutische vorm:

SOLUTION

Samenstelling:

BRIMONIDINE TARTRATE 0.15%

Toedieningsweg:

OPHTHALMIC

Eenheden in pakket:

5ML/10ML

Prescription-type:

Prescription

Therapeutisch gebied:

ALPHA-ADRENERGIC AGONISTS

Product samenvatting:

Active ingredient group (AIG) number: 0131859003; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2008-07-15

Productkenmerken

_BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _
_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
BRIMONIDINE P
Brimonidine Tartrate ophthalmic solution
Sterile Solution, 0.15% w/v, for ophthalmic use
Relatively Selective α
2
-Adrenoceptor Agonist
ATC code: S01EA05
AA PHARMA INC
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
July 15, 2008
Date of Revision:
August 29, 2023
Submission Control Number: 273876
_BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _
_Page 2 of 30 _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
4
4.1 Dosing Considerations
......................................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
................................................................. 5
4.4 Administration
...................................